Weekly roundup: Poolbeg’s progress, Asabys’ strategic expansion, and what to expect at Optimum’s Healthcare Investor Conference
Poolbeg Pharma plc – Interim Results for the six months to 30 June 2025
Poolbeg Pharma, a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announced its unaudited interim results for the six months to 30 June 2025. The company says its well-funded with multiple upcoming clinical milestones.
Asabys Partners integrates Aliath Bioventures Life Sciences Investment Platform in a strategic move with AltamarCAM
Asabys Partners, a Spanish venture capital firm specialised in healthcare, and AltamarCAM Partners, a global investment firm specialised in private markets, have agreed to integrate Aliath Bioventures (formerly Alta Life Sciences), AltamarCAM’s life sciences team, into Asabys and to jointly co-manage the Alta Life Sciences Spain I FCR fund. With the strategic unification, Asabys’ assets under management will expand from €300 million to over €400 million as the company aims to surpass €1 billion in assets under management by 2030.
👥 Optimum’s 17th Annual Healthcare Conference
Have you been watching Optimum TV’s mini-series Countdown to Conference? Ahead of Optimum’s 17th Annual Healthcare Investor Conference being held next Thursday 9th October in London, Optimum TV talked to some of the illustrious speakers on the agenda.
Episode 3: We sat down with Antoine Papiernik, Chairman and Managing Partner at Sofinnova Partners and a seasoned life science investor. Antoine shared his insights into today’s investment landscape – speaking with optimism about the future of healthcare and the critical importance of “picking winners” and backing them with conviction. Watch the episode here.
Episode 2: Experienced life science investor Søren Møller, Managing Partner of Novo Holdings Seed Investments, talks about the up-and-down year 2025 is proving to be for life sciences, how this has impacted investment decisions, and the importance of “ploughing on”. Watch the episode here
Episode 1: Guest Philip Brainin, Associate at Sound Bioventures, discusses why junior VCs are vital to the industry, why he picked venture capital over being a doctor or pursuing academic research, and how we can better measure the true value of innovative medicines. Watch the episode here.
🔥Hot topic
Autumn is here – which means peak conference season in the world of life science investment. Are you prepared to capitalise on the opportunities it offers, asks this week’s Hot Topic. Read it below.
Sector moves
Keep up to date with the latest industry moves here.
That’s all folks! To stay in the know – subscribe to Optimum’s weekly wrap-up today!
